Drug intelligence / Profile preview

AVI-104

Development stage: Preclinical
Lead developer: AbVision
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AVI-104 is an investigational **monoclonal antibody** cancer program from **AbVision**. Publicly available pipeline information identifies it as an oncology antibody in **early discovery**, but does **not disclose a molecular target, mechanism, specific cancer indication, formulation, or route of administration**. Based on the available source context, AVI-104 should currently be understood as an undisclosed preclinical-stage AbVision antibody asset for cancer rather than a clinically characterized therapeutic candidate.

Other names: AVI-104-AbVision-monoclonal antibody-cancerAVI104-AbVision-monoclonal antibody-cancerAVI 104-AbVision-monoclonal antibody-cancer

Beyond the preview

Go deeper on AVI-104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVI-104.

Explore the full profile